NCT06232122Recruiting
Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer
Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer With CA125 Elevation From Complete Response After Therapy
Source: ClinicalTrials.gov · Last updated 30 Jan 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A prospective cohort imaging study in a single institution to evaluate 68Ga- FAPI-46 and 18F-FDG PET/CT imaging for detecting recurrent tumor lesions in patients of ovarian cancer with CA125 elevation from complete response after therapy
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 20 Jan 2024
- Start date
- 1 Aug 2022
- Primary completion date
- 31 Jul 2028
- Lead sponsor
- Chang Gung Memorial Hospital
- Diseases
- Ovarian cancer
- NCT number
- NCT06232122
What you commit to
- Study type: Interventional
- Planned participants: 45
- From 1 Aug 2022 to the primary completion date, 31 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with history of other malignancy
- Known allergic reactions to components of the radiopharmaceutical solutions for intravenous injection for 68Ga-FAPI-46 or 18F-FDG imaging studies
Lab values
- Patients with fasting fingerstick glucose level higher than 200 mg/dl
Other
- Patients who are pregnant or lactating
- Patients who are incapable of lying still for 30 minutes to receive the PET/CT scan as assessed by investigators
Who the study is looking for
- Pathologically proven ovarian cancer with complete response after therapy
- Age between 30 and 80
- Elevation of serum CA125 value above the normal range (\>35 U/mL) or doubling of serum CA125 value within the normal range
- ECOG performance status grade 0 or 1 and willing to receive further therapy if disease recurrence is confirmed
- Willing to enter this prospective study with signed informed consent form
Age in the registry: 30 years to 80 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chang Gung Memorial Hospital Linkou Branch Coordinator of this site? Confirm its status | Taoyuan City | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.